CAR-T Cell Therapy
CAR-T cell therapy is the E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学 frame for chimeric antigen receptor T-cell therapy, where immune cells are engineered to recognize cancer antigens and attack cancer cells. [[LiuCheng|刘诚]] emphasizes that CAR-T is a live-cell therapy: living immune cells are modified so they can kill living cancer cells.
The episode treats CAR-T as a shift in cancer-treatment logic. Chemotherapy, targeted therapy, ADCs, surgery, and radiation mostly apply external killing or removal, while CAR-T tries to solve the Cancer Immune Recognition Problem by redirecting the patient’s immune system. The source’s optimism is strongest in blood cancers, where circulating cancer cells are easier for engineered T cells to reach, and more cautious in solid tumors, where Solid Tumor CAR-T Constraints and the Tumor Microenvironment still dominate.
Key Claims
- CAR-T combines target recognition with T-cell activation, letting immune cells find and attack cells expressing a chosen antigen.
- Ex Vivo CAR-T Manufacturing is currently powerful but expensive and slow because each autologous product is manufactured for one patient.
- In Vivo CAR-T tries to move CAR-T generation into the patient, making it more like an injectable scalable product, but specificity and dose control remain unresolved.
- Allogeneic CAR-T aims for off-the-shelf supply but faces immune-rejection and persistence problems in Liu’s account.
- Cytokine Release Syndrome is a major safety constraint created by excessive immune activation.
Connections
- [[LiuCheng|刘诚]] and Eureka Therapeutics - guest and company grounding the concept.
- Cancer Immune Recognition Problem and Cancer Vaccine Platform - adjacent immune-recognition approaches to cancer.
- Ex Vivo CAR-T Manufacturing, In Vivo CAR-T, and Allogeneic CAR-T - CAR-T production and sourcing routes.
- Solid Tumor CAR-T Constraints, Tumor Microenvironment, and Cytokine Release Syndrome - efficacy and safety limits.
- Legend Biotech / 南京传奇 and Johnson & Johnson / 强生 - commercialization case named in the source.